Study #2017-0141
An Open-label, Multicenter, Phase 1 Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A, With or Without Single-dose Obinutuzumab Pre-treatment, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
Description
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Information and next steps
Disease:
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
Study phase:
I/II
Physician name:
Loretta Nastoupil
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.